Testicular CancerTRANSCEND-XRNCT07571499
Helping Young People With Testicular Cancer Using Virtual and Extended Reality
A study testing Digital tool using extended reality in people with Testicular Cancer and Testis Cancer, run by Gustave Roussy, Cancer Campus, Grand Paris.
Trial summary
TRANSCEND-XR is a European research project designed to better support adolescents and young adults who have been cured of testicular cancer. Even after treatment has ended, many young people continue to face physical, psychological, or social difficulties that are often poorly understood and insufficiently addressed. Read more about this study
- Who is it for?
- Ages 15 to 39 years, men only
- Conditions the study is for
- Testicular Cancer, Testis Cancer, AYA Cancer Survivors
- What is being tested?
- Digital tool using extended reality
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 245 participants
- Where
- No sites listed yet
- Study dates
- 4 Jan 2027to 30 Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 39 years
- Men only
- No healthy volunteers
- Child, Adult
Who may be able to join
- Any person assigned male at birth who is diagnosed with stage I-III TC (germ cell tumour of the testicles).
- Aged between 15 and 39 years at the time of study inclusion.
- Completed curative treatment comprising of at least one standard treatment modality (surgery, chemotherapy and/or radiotherapy) for treatment of their cancer. A maximum of 9 months from the end of curative treatment will be allowed.
- Permitted treatment modalities:
- Localised disease: orchiectomy with or without chemotherapy and/or radiotherapy.
- Metastatic disease: orchiectomy and chemotherapy or radiotherapy or retroperitoneal surgery, or a combination of aforementioned treatments. First-line treatment only allowed.
Show all 10Show fewer
- Willing and able to provide a valid and signed informed consent and/or assent, as appropriate.
- ECOG performance status 0-2.
- Patients accept to use personal smartphone
- Patients able to read and understand the local language
Who cannot join
- Non-testicular germ cell tumours (e.g., mediastinal primary or retroperitoneal primary tumours).
- Non-germ cell TC.
- Previous chemotherapy, radiotherapy, or surgery for TC other than that allowed in IC 4.
- History of contralateral TC.
- Any illness that would prevent the AYA TC survivor from giving a valid and signed informed consent, as assessed by the investigator.
- Any illness that might be exacerbated by the use of an XR digital tool, as assessed by the investigator, including history of severe motion sickness, brain lesions and epilepsy.
Show all 9Show fewer
- Uncontrolled medical condition such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease (including but not limited to grade 2 or higher cardiac failure, arrythmia, unstable angina, history of myocardial infract in the 6 months which, in the opinion of the treating physician, would influence the assessment of long-term side effect of TC treatment.
- AYA TC survivors with a "currently active" second malignancy other than non-melanoma skin cancers, superficial non-invasive (pTa or pTis) TCC of the bladder, or intratubular germ cell neoplasia. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years.
- Chemotherapy or radiotherapy for malignant disease other than TC within the past 3 years.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Adeline Salasc contact
About this study
Official title: Addressing TesticulaR cANcer Unmet Supportive CarE NeeDs in Adolescents and Young Adults Using eXtended Reality
TRANSCEND-XR is a European research project designed to better support adolescents and young adults who have been cured of testicular cancer. Even after treatment has ended, many young people continue to face physical, psychological, or social difficulties that are often poorly understood and insufficiently addressed.
The project aims to develop an innovative digital tool using extended reality (XR) to help these young people better understand the potential long-term effects of the disease and its treatments, recognize signs that require medical attention, and become more active participants in their own health follow-up.
Read more
TRANSCEND-XR first includes a pilot phase to test feasibility and improve the tool, followed by a larger clinical study comparing its use with usual medical follow-up. Researchers will assess, in particular, its impact on patients' knowledge, quality of life, and ability to seek help.
The ultimate goal is to sustainably improve information, autonomy, and well-being among young survivors of testicular cancer through a digital approach tailored to their needs and daily practices.
Read the detailed description
Testicular cancer is a rare cancer, but it mainly affects adolescents and young adults. Today, thanks to the effectiveness of treatments, the vast majority of patients are cured. However, even after treatment has ended, many young people continue to live with long-term consequences, known as "late effects." These effects can vary widely and may include persistent fatigue, pain, hormonal or sexual problems, psychological difficulties such as anxiety or stress, as well as impacts on social life, relationships, education, or professional life.
These difficulties are often poorly understood by patients themselves, sometimes insufficiently addressed during medical follow-up, and may last for several years. Many young people feel inadequately informed, isolated, or unsure about when and how to seek help. Although essential, standard medical follow-up does not always fully address all of these supportive care needs.
It is within this context that the TRANSCEND-XR project was created. TRANSCEND-XR is a European research project coordinated by Gustave Roussy, aiming to develop and evaluate an innovative digital tool based on extended reality (XR) for adolescents and young adults treated for testicular cancer.
TRANSCEND-XR seeks to help young survivors better understand their disease and the treatments they have received, learn about potential long-term effects, recognize symptoms that require medical attention, and adopt health-promoting behaviors. The tool also aims to strengthen their autonomy, confidence, and ability to take an active role in their own follow-up care.
The project is carried out in two main phases. A first pilot study, conducted with a small number of participants across several countries, assesses the feasibility, usability, and acceptability of the tool and allows it to be improved based on patient feedback. A second phase involves a larger clinical study comparing young people who use the TRANSCEND-XR tool with others who receive standard follow-up care only. Researchers will evaluate, in particular, the impact on patients' knowledge, quality of life, supportive care needs, help-seeking behavior, and engagement in long-term follow-up.
Beyond medical outcomes, TRANSCEND-XR also focuses on user experience, digital accessibility, ethical considerations, and equity, in order to offer a solution that is truly adapted to young people's needs and everyday practices.
In summary, TRANSCEND-XR aims to sustainably improve information, well-being, and quality of life for young survivors of testicular cancer, using innovative digital tools to better address the challenges of life after cancer.
- Being tested
- Digital tool using extended reality
- Keywords
- Testicular cancer survivors, Adolescents and young adults (AYA), Survivorship care, Supportive care needs, Late effects of cancer treatment, Post-cancer follow-up, Quality of life, Patient education, Extended reality (XR), Virtual reality in healthcare, Digital health intervention, Immersive digital tools, Long-term cancer effects
- Medical subject headings
- Testicular Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital tool using extended realityOther
TRANSCEND-XR is a digital educational intervention based on extended reality (XR), designed for adolescents and young adults who have completed curative treatment for testicular cancer.
It provides interactive and immersive content aimed at improving understanding of the late effects of treatment, whether physical, psychological, or social. The tool helps users recognize symptoms that require medical attention, strengthen their health knowledge, and adopt behaviors that support long-term follow-up, such as self-examination and appropriate use of healthcare services.
Co-designed with patients and healthcare professionals, TRANSCEND-XR aims to enhance autonomy, confidence, and engagement of young survivors in managing their health after cancer.
| Study group | Role | What they receive |
|---|---|---|
| Intervention arm (arm I) | Experimental | participants will receive, in addition to their standard of care, an educational intervention via the digital tool for a period of 6 months, followed by an additional 12 months of follow-up. Receives: Other: Digital tool using extended reality |
| Control arm (arm C) | No intervention | participants will receive their standard of care, without intervention, for a period of 6 months, followed by an additional 12 months of follow-up. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pilot study: to determine the feasibility of implementing the XR digital tool in AYA survivors of testicular cancer
Assessed by inclusion time, engagement, no major issue with patient feedback
Measured: after 6 months of inclusion
pRCT (Pragmatic Randomized Controlled Trial): knowledge of the late effects of XR digital tool in AYA survivors of testicular cancer
Assessed by analysis of data collected during study visits
Measured: 12 months follow-up (18 months after randomization)
Secondary outcomes (3)
Pilot study: quality of questionnaires used
Assessed by completion rate and number of missing responses
Measured: 9 months after the begin of the study
pRCT (Pragmatic Randomized Controlled Trial): Health-related quality of life
Assessed using the EORTC-QLQ-C30 \& T26 and EQ-5D-5L questionnaires
Measured: at the end of the study (5 years)
pRCT (Pragmatic Randomized Controlled Trial): Supportive care needs
Measured using the CaSUN questionnaire
Measured: at the end of the study (5 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2026
- Study start4 Jan 2027 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Testicular CancerStudies of the same condition, open and under way.
- More trials run by Gustave Roussy, Cancer Campus, Grand ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- TRANSCEND-XR is an international clinical study conducted in two phases. It begins with a non-randomized pilot study aimed at assessing feasibility and optimizing the extended reality digital tool. It is followed by a pragmatic randomized controlled trial comparing two groups: one group receiving usual medical follow-up with the TRANSCEND-XR tool, one group receiving usual medical follow-up alone. The study evaluates the impact of the tool under conditions close to real-world clinical practice among adolescents and young adults who have survived testicular cancer.
- Masking
- None (open label)
- Enrolment
- 245 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Anna Patrikidou, Principal investigator, Gustave Roussy, Cancer Campus, Grand Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07571499
- Sponsor's protocol ID
- 2026-A00740-51
- Other IDs
- CSET number 2026 / 4327
- Acronym
- TRANSCEND-XR
- Status last verified
- Apr 2026
- First submitted
- 23 Apr 2026
- Last updated
- 6 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Raggi D, Gleeson JP, Naoun N, Giannatempo P, Nuzzo A, Reid A, Corrigan L, Jezek D, Chovanec M, Gietema J, Fresneau B, Pais-Vieira C, Alves P, Reid J, Clara MI, Roca-Umbert A, Soares J, Murphy D, Shiely F, McHugh S, Kirby A, Murphy A, Hussain A, Korfage I, Terhaard S, Kubo M, Toygar I, Hegarty J, O'Malley M, Salasc A, Saab MM, Patrikidou A. Cured but What's Next? Rethinking Survivorship Care for Adolescent and Young Adult Testicular Cancer Survivors. Eur Urol Oncol. 2026 Oct 30:S2588-9311(26)00261-0. doi: 10.1016/j.euo.2026.09.013. Online ahead of print.
PubMed 42963238
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Addressing TesticulaR cANcer Unmet Supportive CarE NeeDs in Adolescents and Young Adults Using eXtended Reality
- ClinicalTrials.gov ID
- NCT07571499
- Acronym / sponsor ID
- TRANSCEND-XR / 2026-A00740-51
- Keywords
- Testicular cancer survivors, Adolescents and young adults (AYA), Survivorship care, Supportive care needs, Late effects of cancer treatment, Post-cancer follow-up, Quality of life, Patient education
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 245 participants (estimated)
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisUniversity, hospital or other
- Study start
- 4 Jan 2027 (estimated)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Jun 2029 (estimated)
- First posted
- 6 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
TRANSCEND-XR is a European research project designed to better support adolescents and young adults who have been cured of testicular cancer. Even after treatment has ended, many young people continue to face physical, psychological, or social difficulties that are often poorly understood and insufficiently addressed.
The project aims to develop an innovative digital tool using extended reality (XR) to help these young people better understand the potential long-term effects of the disease and its treatments, recognize signs that require medical attention, and become more active participants in their own health follow-up.
TRANSCEND-XR first includes a pilot phase to test feasibility and improve the tool, followed by a larger clinical study comparing its use with usual medical follow-up. Researchers will assess, in particular, its impact on patients' knowledge, quality of life, and ability to seek help.
The ultimate goal is to sustainably improve information, autonomy, and well-being among young survivors of testicular cancer through a digital approach tailored to their needs and daily practices.
Detailed description
Testicular cancer is a rare cancer, but it mainly affects adolescents and young adults. Today, thanks to the effectiveness of treatments, the vast majority of patients are cured. However, even after treatment has ended, many young people continue to live with long-term consequences, known as "late effects." These effects can vary widely and may include persistent fatigue, pain, hormonal or sexual problems, psychological difficulties such as anxiety or stress, as well as impacts on social life, relationships, education, or professional life.
These difficulties are often poorly understood by patients themselves, sometimes insufficiently addressed during medical follow-up, and may last for several years. Many young people feel inadequately informed, isolated, or unsure about when and how to seek help. Although essential, standard medical follow-up does not always fully address all of these supportive care needs.
It is within this context that the TRANSCEND-XR project was created. TRANSCEND-XR is a European research project coordinated by Gustave Roussy, aiming to develop and evaluate an innovative digital tool based on extended reality (XR) for adolescents and young adults treated for testicular cancer.
TRANSCEND-XR seeks to help young survivors better understand their disease and the treatments they have received, learn about potential long-term effects, recognize symptoms that require medical attention, and adopt health-promoting behaviors. The tool also aims to strengthen their autonomy, confidence, and ability to take an active role in their own follow-up care.
The project is carried out in two main phases. A first pilot study, conducted with a small number of participants across several countries, assesses the feasibility, usability, and acceptability of the tool and allows it to be improved based on patient feedback. A second phase involves a larger clinical study comparing young people who use the TRANSCEND-XR tool with others who receive standard follow-up care only. Researchers will evaluate, in particular, the impact on patients' knowledge, quality of life, supportive care needs, help-seeking behavior, and engagement in long-term follow-up.
Beyond medical outcomes, TRANSCEND-XR also focuses on user experience, digital accessibility, ethical considerations, and equity, in order to offer a solution that is truly adapted to young people's needs and everyday practices.
In summary, TRANSCEND-XR aims to sustainably improve information, well-being, and quality of life for young survivors of testicular cancer, using innovative digital tools to better address the challenges of life after cancer.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- TRANSCEND-XR is an international clinical study conducted in two phases. It begins with a non-randomized pilot study aimed at assessing feasibility and optimizing the extended reality digital tool. It is followed by a pragmatic randomized controlled trial comparing two groups: one group receiving usual medical follow-up with the TRANSCEND-XR tool, one group receiving usual medical follow-up alone. The study evaluates the impact of the tool under conditions close to real-world clinical practice among adolescents and young adults who have survived testicular cancer.
| Arm | Type | Receives |
|---|---|---|
| Intervention arm (arm I) | Experimental | Other: Digital tool using extended realityparticipants will receive, in addition to their standard of care, an educational intervention via the digital tool for a period of 6 months, followed by an additional 12 months of follow-up. |
| Control arm (arm C) | No intervention | –participants will receive their standard of care, without intervention, for a period of 6 months, followed by an additional 12 months of follow-up. |
Who may qualify
- Ages
- 15 to 39 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (10 listed)
- Any person assigned male at birth who is diagnosed with stage I-III TC (germ cell tumour of the testicles).
- Aged between 15 and 39 years at the time of study inclusion.
- Completed curative treatment comprising of at least one standard treatment modality (surgery, chemotherapy and/or radiotherapy) for treatment of their cancer. A maximum of 9 months from the end of curative treatment will be allowed.
- Permitted treatment modalities:
- Willing and able to provide a valid and signed informed consent and/or assent, as appropriate.
Key exclusion criteria (9 listed)
- Non-testicular germ cell tumours (e.g., mediastinal primary or retroperitoneal primary tumours).
- Non-germ cell TC.
- Previous chemotherapy, radiotherapy, or surgery for TC other than that allowed in IC 4.
- History of contralateral TC.
- Any illness that would prevent the AYA TC survivor from giving a valid and signed informed consent, as assessed by the investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Digital tool using extended realityTRANSCEND-XR is a digital educational intervention based on extended reality (XR), designed for adolescents and young adults who have completed curative treatment for testicular cancer. It provides interactive and immersive content aimed at improving understanding of the late effects of treatment, whether physical, psychological, or social. The tool helps users recognize symptoms that require medical attention, strengthen their health knowledge, and adopt behaviors that support long-term follow-up, such as self-examination and appropriate use of healthcare services. Co-designed with patients and healthcare professionals, TRANSCEND-XR aims to enhance autonomy, confidence, and engagement of young survivors in managing their health after cancer. | Other | Intervention arm (arm I) |
Primary outcome
Pilot study: to determine the feasibility of implementing the XR digital tool in AYA survivors of testicular cancer
Time frame: after 6 months of inclusion
Assessed by inclusion time, engagement, no major issue with patient feedback
pRCT (Pragmatic Randomized Controlled Trial): knowledge of the late effects of XR digital tool in AYA survivors of testicular cancer
Time frame: 12 months follow-up (18 months after randomization)
Assessed by analysis of data collected during study visits
3 secondary outcomes
Pilot study: quality of questionnaires used
Time frame: 9 months after the begin of the study
pRCT (Pragmatic Randomized Controlled Trial): Health-related quality of life
Time frame: at the end of the study (5 years)
pRCT (Pragmatic Randomized Controlled Trial): Supportive care needs
Time frame: at the end of the study (5 years)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
- Derived from this study: PubMed 42963238Raggi D, Gleeson JP, Naoun N, Giannatempo P, Nuzzo A, Reid A, Corrigan L, Jezek D, Chovanec M, Gietema J, Fresneau B, Pais-Vieira C, Alves P, Reid J, Clara MI, Roca-Umbert A, Soares J, Murphy D, Shiely F, McHugh S, Kirby A, Murphy A, Hussain A, Korfage I, Terhaard S, Kubo M, Toygar I, Hegarty J, O'Malley M, Salasc A, Saab MM, Patrikidou A. Cured but What's Next? Rethinking Survivorship Care for Adolescent and Young Adult Testicular Cancer Survivors. Eur Urol Oncol. 2026 Oct 30:S2588-9311(26)00261-0. doi: 10.1016/j.euo.2026.09.013. Online ahead of print.
Related trials for Testicular Cancer
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingObservational study
Germ Cell Tumor and Testicular Tumor DNA Registry
Germ Cell Tumor, Testicular Tumor
RecruitingPhase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
RecruitingObservational study
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Testicular Cancer, Survivorship
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Adeline Salasc contact
Anna Patrikidou principal investigator
Gustave Roussy, Cancer Campus, Grand Paris
Questions about this trial
What is this clinical trial studying?
A study testing Digital tool using extended reality in people with Testicular Cancer and Testis Cancer, run by Gustave Roussy, Cancer Campus, Grand Paris.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Anna Patrikidou (+33142114211, anna.patrikidou@gustaveroussy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pilot study: to determine the feasibility of implementing the XR digital tool in AYA survivors of testicular cancer (time frame: after 6 months of inclusion). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07571499, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.